Multiple Sclerosis, Primary Progressive

Also known as: Primary progressive multiple sclerosis / Primary Progressive MS / Primary-progressive Multiple Sclerosis

DrugDrug NameDrug Description
DB11988OcrelizumabOcrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with relapsing or primary progressive forms of multiple sclerosis. It is injection, for intravenous use. Initial U.S. Approval: 2017
DrugDrug NameTargetType
DB11988OcrelizumabB-lymphocyte antigen CD20target
DrugDrug NamePhaseStatusCount
DB01076Atorvastatin1Completed1
DB00257Clotrimazole1Completed1
DB08868Fingolimod1Completed1
DB05259Glatiramer Acetate1Completed1
DB00279Liothyronine1Active Not Recruiting1
DB01110Miconazole1Completed1
DB00073Rituximab1Completed1
DB00857Terbinafine1Completed1
DB00759Tetracycline1Completed1
DB00525Tolnaftate1Completed1
DB11117Undecylenate1Completed1
DB05767Andrographolide1 / 2Recruiting1
DB09081Idebenone1 / 2Active Not Recruiting1
DB09081Idebenone1 / 2Enrolling by Invitation1
DB01285Corticotropin2Recruiting1
DB08908Dimethyl fumarate2Recruiting1
DB04573Estriol2Recruiting1
DB01611Hydroxychloroquine2Recruiting1
DB05266Ibudilast2Active Not Recruiting1
DB06685Laquinimod2Active Not Recruiting1
DB00108Natalizumab2Completed1
DB00717Norethisterone2Recruiting1
DB00624Testosterone2Withdrawn1
DB06637Dalfampridine3Completed1
DB08868Fingolimod3Completed2
DB11988Ocrelizumab3Active Not Recruiting1
DB11988Ocrelizumab3Recruiting1
DB06637Dalfampridine4Active Not Recruiting1
DB09150Fludeoxyglucose F-18Not AvailableRecruiting1